IBM Watson to Find Out Why Cancer Becomes Drug Registant

Computer Business Review – IBM Watson Health, the Broad Institute of MIT and Harvard have partnered together to research cancer drug resistance. The $50m project will take advantage of Watson’s computational and machine learning methods along with project researchers to understand how cancers turn resistant to certain drug therapies. Drug resistance causes nearly 600,000 cancer deaths in the US each year. The Broad Institute will specifically look at tumor genome sequence data from cancer patients while the IBM team will use Watson to identify and analyze genomic patterns. Watson has already proved it can help researchers in the fight against cancer during a recent partnership with the University of North Carolina. LINK